Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.88 |
| ▸ | MAPK13 | O15264 | 7/20 | 0.88 |
| ▸ | MAPK12 | P53778 | 7/20 | 0.88 |
| ▸ | MAPK11 | Q15759 | 7/20 | 0.88 |
| ▸ | GCGR | P47871 | 5/20 | 0.88 |
| ▸ | MAPT | P10636 | 5/20 | 0.88 |
| ▸ | TP53 | P04637 | 4/20 | 0.88 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.66 |
| ▸ | RAF1 | P04049 | 3/20 | 0.64 |
| ▸ | BRAF | P15056 | 2/20 | 0.64 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.62 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | CIT | O14578 | 1/20 | 0.62 |
| ▸ | GAK | O14976 | 1/20 | 0.62 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.62 |
| ▸ | BRD4 | O60885 | 1/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.62 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12561692 | 0.94 | MAPK13 (1.00) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL14045551 | 0.93 | MAPK14 (0.77) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL8010209 | 0.91 | NOX1 (0.76) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL28158811 | 0.91 | MAPK13 (0.86) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL14220431 | 0.89 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL11176392 | 0.85 | MAPK13 (1.00) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL9619859 | 0.85 | MAPK13 (0.85) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL15401173 | 0.85 | MAPK13 (0.85) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL252964 | 0.85 | MAPK13 (0.85) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL5307418 | 0.85 | MAPK13 (0.85) | MAPK14MAPK13MAPK12MAPK11GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692113-B1 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS | LORUS THERAPEUTICS INC (CA) | 2017-09-27 | — | — | EP | disclosed |
| US-20150374669-A1 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS | LORUS THERAPEUTICS INC. (CA) | 2015-12-31 | — | — | US | disclosed |
| US-20150374669-A1 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS | LORUS THERAPEUTICS INC. (CA) | 2015-12-31 | — | — | US | disclosed |
| US-8969372-B2 | Aryl imidazoles and their use as anti-cancer agents | Aptose Boisciences Inc. (CA) | 2015-03-03 | — | — | US | disclosed |
| US-8969372-B2 | Aryl imidazoles and their use as anti-cancer agents | Aptose Boisciences Inc. (CA) | 2015-03-03 | — | — | US | disclosed |
| US-20080262015-A9 | Aryl imidazoles and their use as anti-cancer agents | LORUS THERAPEUTICS INC. (CA) | 2008-10-23 | — | — | US | disclosed |
| US-20080262015-A9 | Aryl imidazoles and their use as anti-cancer agents | LORUS THERAPEUTICS INC. (CA) | 2008-10-23 | — | — | US | disclosed |
| WO-2005047266-A9 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS | LORUS THERAPEUTICS INC (CA) | 2008-04-17 | — | — | WO | disclosed |
| US-20070123553-A1 | Aryl imidazoles and their use as anti-cancer agents | LORUS THERAPEUTICS INC. (CA) | 2007-05-31 | — | — | US | disclosed |
| US-20070123553-A1 | Aryl imidazoles and their use as anti-cancer agents | LORUS THERAPEUTICS INC. (CA) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123553-A1 | Aryl imidazoles and their use as anti-cancer agents | AHR, AADAC, CBR3 | MAPK14 3469/4885MAPK13 4059/4885MAPK12 3204/4885 |
| US-20150374669-A1 | ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS | AHR, CBR3, AADAC | MAPK14 3647/4885MAPK13 4087/4885MAPK12 3446/4885 |
| US-20080262015-A9 | Aryl imidazoles and their use as anti-cancer agents | AHR, AADAC, CBR3 | MAPK14 3469/4885MAPK13 4059/4885MAPK12 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.